Clinical Trial Update: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating FG-3246 in metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• FG-3246

Snippet

Sponsor: Kyntra Bio | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: RECRUITING